Refractory status epilepticus (RSE) is a common problem in intensive care units and emergency departments. The important risk factor predisposing patients with SE to RSE is delay in receiving treatment. Self-sustaining SE is associated with progressive, time-dependent development of pharmacoresistance. Early termination of convulsive SE by aggressive treatment is the best way to prevent RSE. RSE once develop, requires more aggressive treatment as it is associated with higher mortality and morbidity. To date, no randomized controlled trials have been done for RSE. The most experience exists with coma inducing agents like pentobarbital, midazolam and propofol. New evidence suggests for the possible role of newer AEDs.
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defined as seizure activity that continues after first-and second line therapy has failed.
[4] However the proposed criteria vary in the number of AEDs (e.g., 2 [5] [6] [7] [8] [9] or 3 [10] [11] [12] [13] ) failed and in the duration of seizure activity (e.g., ranging from <1 [5, 9, 11, 13] at least 1 [7] 2 [6, 8] hours). Recently Holtkamp and colleagues [14] have coined the term "malignant" SE for the most severe variant of SE with persistent epileptic activity even after high dose anesthetics.
Epidemiology
RSE is a common problem in intensive care units and emergency departments. Estimates of the frequency of RSE in patients with SE have ranged from 31 to 44%. [15, 16] The proportion of patients with RSE in the cohort reported by Rossetti et al [17] was 38% when considering all episodes and was 44% when considering only incidence cases. In the VA Cooperative Study, 38% of patients with "overt" SE and 82% of patients with "subtle" SE continued to have seizures after receiving 2 AEDs.
[2]
Status epilepticus (SE) is a frequent neurological emergency RSE is associated with high mortality and a significant associated with an annual incidence between 3.86-38 per 100,000 morbidity; only about a third of patients return to their pre-morbid individuals. The incidence of SE has a bimodal distribution with state. [18] In the VA Cooperative study [2] outcomes 30 days after peaks in children aged less than a year and the elderly.
[1] Although treatment were significantly worse for patients with "subtle" SE. conventional antiepileptic drugs (AED) can terminate SE in most At 30 days, only 8.8% of patients had been discharged from the cases, a substantial minority of patients develop medically refractory hospital and 26.5% were still in the hospital and the mortality SE (RSE). In Veteran Administrative (VA) Cooperative study [2] was 64.7%. In the recent studies the reported mortality rates or first treatment regimen was successful in 55.5% of patients with "overt" SE, but in only 14.9% of those with "subtle" SE. Subsequent treatments of patients, who did not respond to first line agent, indicates that the aggregate response rate was 7% to second-line agents and 2.3% to third-line agents. Only 5% of patients with SE who did not respond to lorazepam and phenytoin therapy, responded to phenobarbital administration. 
Definition
Although the entity of RSE is widely recognized and discussed, a standard definition has not yet been evolved and is usually varied between 16 to 23%. [15] [16] [17] In a retrospective study the outcome was independent of specific coma inducing agents used and the extent of EEG burst suppression, suggesting that the underlying cause represents its main determinant. [17] 
Risk factors
RSE is more prevalent in incident than in recurrent SE. [17] Risk factors predisposing patients to RSE include delay in receiving treatment, infections of central nervous system (CNS), metabolic encephalopathy and hypoxia. [15, 19] Encephalitis is a predictor for RSE, which is associated with markedly poor Murthy JMK: Refractory status epilepticus outcome, in particular, the development of post-SE symptomatic epilepsy. [16] The patient at risk for malignant SE is typically young and suffers from encephalitis. [16] Pathophysiology SE refers to a condition in which there is a failure of the "normal" factors that serve to terminate a typical seizure. y-Aminobutyric acid (GABA) receptor-mediated inhibition may be responsible for the normal termination of a seizure. In addition, the activation (NCSE) in patients who do not regain consciousness after clinical seizure stops. Electrographic seizures may persist in patients after convulsive SE. In one study cEEG demonstrated electrographic seizures in 48% of patients and 14% manifested NCSE.
[33] In the VA study, 20% of clinically controlled convulsive SE patients were still seizing on EEG.
[2] Mortality in patients in whom cEEG demonstrates electrographic seizures and NCSE is high. cEEG monitoring is required in patients with RSE during continuous intravenous therapy to monitor seizure activity and to titrate the drug dosage to achieve burst suppression pattern of the N-methyl-D aspartate (NMDA) receptor by the excitatory and during the withdrawal of anesthetic therapy. However the neurotransmitter glutamate may be required for the propagation major limiting factor may be lack cEEG monitoring facility in of seizure activity. [20] SE that is refractory to treatment may be the many intensive care units. result of several processes [ Table 1 ] and has been attributed to a mechanistic shift from inadequate GABAergic inhibitory receptor-
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mediated transmission to excessive NMDA excitatory receptor mediated transmission. [21] [22] [23] [24] [25] [26] In experimental models, resistance RSE requires more aggressive treatment and however, the to both benzodiazepines and barbiturates develops during optimal treatment has not been defined. Patients should be treated prolonged seizures and it has been hypothesized that prolonged in intensive care unit, as artificial ventilation and hemodynamic seizure activity alters the structure and/or function of GABA support is required. These patients generally require intravenous A fluids and vasopressors to treat hypotension associated with high SE induced neuronal death is morphologically necrotic and is dose intravenous use of anesthetic agents. In a third of adults in initiated by excessive glutamate release, which activates SE, arterial pH falls below 7;
[34] the main contribution to this postsynaptic NMDA receptors and triggers receptor-mediated change is lactic acidosis from skeletal muscle, [35] which responds calcium influx (excitotoxicity). This results in a cascade of events well to oxygen and control of convulsive activity. Mild acidosis and cell death.
[28]
might be an anticonvulsant [36] and neuroprotective.
[37] The usual The alterations in inhibitory and excitatory pathways have practice is to treat with bicarbonate if the patient is hypotensive important implications for the pharmacological management of and arterial pH if it is < 7 due to metabolic acidosis. Control of SE. Another important aspect of self-sustaining SE is the hypothermia is neuroprotective. [38, 39] progressive, time-dependent development of pharmacoresistance. Currently recommended agents acts primarily through the Pharmacological treatment receptor and have been shown to become less effective in To date, no randomized controlled trials have been done for SE SE of longer duration. Drugs shown to be effective in RSE act at refractory to first-and second-line therapy. The most experience different receptor sites other than benzodiazepine receptor site, exists with continuous infusion (cIV) of pentobarbital, midazolam propofol acts at a site distinct from the benzodiazepine and and propofol [18, 40, 41] [ Table 2 ]. The best comparative information barbiturate binding sites, isoflurane acts by potentiation of comes from the systematic review by Claassen and colleagues. [18] inhibitory postsynaptic GABA receptor-mediated currents, No difference was found in mortality among the groups treated A receptors.
[27]
GABA A although effects on thalamo-cortical pathways also have been implicated.
[27-31]
Continuous EEG Monitoring
Though continuous EEG monitoring (cEEG) has a definite place in the diagnosis and management of nonconvulsive status epilepticus (NCSE), its place in the management of convulsive SE is still unclear.
[32] However EEG is useful in determining whether seizures have completely stopped, as well as in diagnosing electrographic seizures or nonconvulsive status epilepticus with cIV propofol, cIV midazolam and cIV pentobarbital. Mortality was related to patient's age and duration of SE rather than AED choice. A recent retrospective study investigated the effect on RSE prognosis of various coma-inducing pharmacologic options. [17] Mortality and likelihood of the patient's condition returning to clinical baseline at discharge did not differ significantly among the three arms, barbiturates (pentobarbital and phenobarbital), propofol and midazolam. This study did not find any evidence for mortality related to propofol infusion syndrome.
Traditionally, barbiturates such as pentobarbital or thiopental have been used to terminate RSE, inducing coma and EEG Murthy JMK: Refractory status epilepticus suppression. [11, [42] [43] [44] However their effectiveness has not been studied systematically. In a systematic review of 109 adult patients with RSE who were treated with pentobarbital 8% experienced acute failure; 12%, breakthrough seizures; 43%, withdrawal seizures within 48 hours; and 8%, refractory hypotension during the therapy.
[17] EEG burst suppression or complete suppression has been achieved more frequently in episodes treated with barbiturates. [17, 18] Pentobarbital use is also often accompanied by prolonged sedation and life threatening infections.
[45] Episodes treated with barbiturates were associated with significantly longer up to days.
[52] After 24-48 h, the dose of the drug must often be increased severalfold to maintain seizure control. Clinical experience with midazolam for RSE is limited. The reported failed treatment with midazolam ranges between 14 to 18%. [52] [53] [54] [55] [56] [57] In the series of Claassen and colleagues [57] acute treatment failure occurred in 18% of episodes, breakthrough seizures in 56%, post treatment seizures in 68% and ultimate treatment failure in 18%. The authors suggest that titrating continuous intravenous midazolam to burst suppression, more aggressive treatment with concurrent AED or a longer period of initial treatment may reduce the high is a GABA hospital stay for surviving patients compared with episodes in proportion of patients with RSE who relapse after midazolam is which barbiturates were not used. [17] discontinued. In this series only 24% had an immediate and Superior pharmacokinetics and favorable adverse effect profile sustained response. makes propofol the drug of choice. The two main advantages of propofol are a rapid onset and short duration of action. Propofol Other Pharmacological treatment agonist that suppresses seizure activity via GABA-High dose phenobarbital mediated inhibition of neuronal firing. Other mechanisms of action High dose of phenobarbital with serum levels of 100 to 200 ug/ include inhibition of N-methyl-D aspartate receptor and ml, has been found effective and safe in the treatment of RSE in modulation of calcium influx through slow calcium ion channels. children.
[58] In another study a very high dose phenobarbital at The safety of propofol was further supported in recent accumulated daily doses up to 80 mg/kg, with a resulting serum retrospective series both in adults [40] and children. [41] A prospective level of more than 1000 mumol/l has been shown to effective in study has also shown its efficacy in RSE. [46] In a retrospective achieving seizure control in children with RSE. In this study the series by Rossetti et al [40] in which 27 patients who failed to adverse effects were milder compared with thiopental infusion.
[59]
intravenous clonazepam and phenytoin therapy were induced into burst suppression pattern on cEEG with cIV propofol at a Ketamine dose of 2.1 to 13 mg/kg/h for 1 to 9 days while continuing Ketamine, a NMDA antagonist, has been proved useful in clonazepam infusion. RSE was successfully treated with propofol RSE [60] and it is also a neuroprotective. [61] However, because in 21 (67%) episodes. Seven deaths (23%) wee reported and ketamine can raise intracranial pressure, the absence of none were attributable directly to propofol use and no patient intracranial mass lesion should be confirmed by neuroimaging. experienced propofol infusion syndrome. In pediatric RSE also The experience with this agent in RSE is very limited. propofol has been shown to be a safe and effective drug, 14 (64%) of the 22 episodes could be adequately controlled. Two patients Inhalational Anesthetics who were successfully treated with propofol died and the death Inhalational anesthesia (IA) is an alternative approach to the was related to the underlying etiology and not to the use of treatment of RSE. Its attractive feature include efficacy, rapid propofol.
[41] However propofol may cause metabolic acidosis and onset of action and the ability to titrate the doses according to the cardiovascular collapse with prolonged use in children and deaths effects demonstrated on the EEG. [62, 63] Of the various agents, have been reported, [47, 48] the propofol infusion syndrome. [49] isoflurane and desflurane are the two agents that have been A Propofol should therefore be used with caution in children, ideally for short time only and the infusion rate should not exceed 67 ug/ kg/min. [50] In a prospective study the quality of burst suppression was unsatisfactory in most patients. The maintenance of continuous burst suppression is difficult and vigilant titrating of dosage of propofol is necessary under cEEG monitoring. [46] Midazolam is an effective, short acting benzodiazepine that when given as an infusion has an efficacy in RSE, including at sub anesthetic doses. It has the advantages of rapid onset of activity and greater water solubility, avoiding the problem of metabolic acidosis from the propylene glycol vehicle of other benzodiazepines and barbiturates. Midazolam binds to GABAA receptors and augments GABAergic transmission, there by imparting anticonvulsant and sedative-hypnotic properties.
[51] Duration of antiepileptic effects is minutes to hours. The elimination half-life is 1.5 to 3.5 hours initially. With prolonged use, there may be tolerance, tachyphylaxis and significant prolongation of half-life, administrated for RSE because of their safety associated with long-term administration. [64] In a recent retrospective study, seven patients with RSE were initiated to IAs (all patients to isoflurane and one patient in addition to desfluratne) after 1 to 103 (mean,19) days. They received multiple AEDs (mean 10, range 7 -15) in addition to IAs. Regardless of seizure type, isoflurane and desflurane consistently stopped epileptic discharges with adequate, sustained electrographic burst suppression within minutes of initiating IA therapy. Four patients had good outcomes. Prolonged use of IAs is well tolerated. [64] Newer AEDs
The use of newer AEDS in the treatment of RSE has not been studied systematically. In 6 patients with RSE unresponsive to sequential trials of multiple agents, a suspension of topiramate administered via nasogastric tube was effective in aborting RSE. Effective dosages ranged from 300 to 1,600 mg/d.
[65] RSE was Murthy JMK: Refractory status epilepticus terminated in three children with topiramate loading, 5 mg/kg/ day. [66] Seizure control has been achieved in patients with RSE by administration of levetiracetam (500-3000 mg/day) by nasogastric route. [67] Injectable levetiracetam formulation is available and the pharmacokinetics of levetiracetam administered by IV infusion was comparable across all dose groups and infusion rates and the pharmacokinetic profile was consistent with that for levetiracetam administered orally.
[68] Well designed studies are needed to determine the place of newer AEDs as the use of drugs Target: EEG burst suppression can avoid pharmacologic coma.
Target of treatment-burst suppression
Experimental studies demonstrated maximal depression of cerebral metabolism with barbiturates with burst suppression intervals of 30 seconds.
[69] Burst suppression and isoelectric controlled trials have been done for RSE. The most experience background EEG have been shown to be accompanied by fewer exists with coma inducing agents like pentobarbital, midazolam recurrent seizures than simply stopping seizures. [18] There is and propofol. New evidence suggests for the possible role of newer uncertainty about the optimal extent of EEG suppression in RSE. AEDs [ Figure 1 ]. Several authors used different burst suppression intervals. Kofke et al [70] RSE. [17] principle be continued as oral maintenance therapy. In others, unless relatively short-lived treatment is anticipated, the preference is to initiate oral maintenance therapy, valproate or carbamazepine, starting immediately at standard doses.
[72] If additional medication is needed, the most appropriate AEDs are topiramate and levetiracetam as these drugs can be started at high doses with a low risk of idiosyncratic reactions. [73] 
Conclusions
The important risk factor predisposing patients with SE to RSE is delay in receiving treatment. Self-sustaining SE is associated with progressive, time-dependent development of pharmacoresistance. Early termination of convulsive SE by aggressive treatment is the best way to prevent RSE. RSE once develop, requires more aggressive treatment as it is associated with higher mortality and morbidity. To date, no randomized ) .
